Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)

v3.22.1
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Other Comprehensive Loss
Beginning balance at Dec. 31, 2020 $ (1,979) $ 6 $ 144,156 $ (145,803) $ (338)
Beginning balance (in shares) at Dec. 31, 2020   56,371,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options, net of vesting of restricted shares 65   65    
Exercise of stock options, net of vesting of restricted shares (in shares)   120,000      
Release of restricted stock (in shares)   183,000      
Issuance of common stock for payment of board of director fees 66   66    
Issuance of common stock for payment of legal and board of director fees (in shares)   99,000      
Sales of common stock, net of issuance costs 29,705 $ 1 29,704    
Sales of common stock, net of issuance costs (in shares)   14,431,000      
Stock-based compensation expense 1,055   1,055    
Cumulative translation adjustment 10       10
Net loss (14,307)     (14,307)  
Ending balance at Mar. 31, 2021 14,615 $ 7 175,046 (160,110) (328)
Ending balance (in shares) at Mar. 31, 2021   71,204,000      
Beginning balance at Dec. 31, 2021 65,277 $ 10 264,944 (199,325) (352)
Beginning balance (in shares) at Dec. 31, 2021   96,752,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options, net of vesting of restricted shares $ 16   16    
Exercise of stock options, net of vesting of restricted shares (in shares) 22,757 23,000      
Release of restricted stock (in shares)   92,000      
Issuance of common stock in connection with acquisition of Lyte Technology, Inc. $ 1,125   1,125    
Issuance of common stock in connection with acquisition of Lyte Technology, Inc. (in shares)   384,000      
Stock-based compensation expense 521   521    
Cumulative translation adjustment (32)       (32)
Net loss (14,917)     (14,917)  
Ending balance at Mar. 31, 2022 $ 51,990 $ 10 $ 266,606 $ (214,242) $ (384)
Ending balance (in shares) at Mar. 31, 2022   97,251,000